Connection Node Design and Performance Optimization of Girder Truss

Girder truss is a kind of high-performance truss, which is combined with some single trusses by connectors. It is the common structural form of the key-bearing node in the modern wood structure floor and roof structure system. With the development of the sponge city and green building in China, girder truss is widely used in wood structure buildings and re-roofing project for its lightweight, high strength, good seismic performance, simple construction, design flexibility, and other excellent characteristics. Since the stress environment of girder truss is more complicated than single wood truss, the wood girder truss needs higher bearing capacity. This chapter emphatically provides a theoretical basis for practical engineering and mainly introduces a new type of girder truss connected with different diameters of wood dowels. The deformation of each node in the static loading process is measured in situ and continuously by using the self-designed loading device and the advanced measuring system. Research contents include the increasing effect of girder truss than single truss and influence of different connection modes on the mechanical properties of girder trusses. We can restore the mechanical properties and failure mechanism from the two aspects of phenomena and mechanism by comparing the test results

Response of Mouse Zygotes Treated with Mild Hydrogen Peroxide as a Model to Reveal Novel Mechanisms of Oxidative Stress-Induced Injury in Early Embryos

Our study aimed to develop embryo models to evaluate the impact of oxidative stress on embryo development. Mouse zygotes, which stayed at G1 phase, were treated with prepared culture medium (containing 0.00, 0.01, 0.02, 0.03, 0.04, 0.05, or 0.1 mM hydrogen peroxide (H2O2)) for 30 min in experiment 1. The dose-effects of H2O2 on embryo development were investigated via comparisons of the formation rate at each stage (2- and 4-cell embryos and blastocysts). Experiment 2 was carried out to compare behaviors of embryos in a mild oxidative-stressed status (0.03 mM H2O2) with those in a control (0 mM H2O2). Reactive oxygen species (ROS) levels, variation of mitochondrial membrane potential (MMP), expression of γH2AX, and cell apoptosis rate of blastocyst were detected. We observed a dose-dependent decrease on cleavage and blastocyst rates. Besides, higher level of ROS, rapid reduction of MMP, and the appearance of γH2AX revealed that embryos are injured early in mild oxidative stress. Additionally, γH2AX may involve during DNA damage response in early embryos. And the apoptotic rate of blastocyst may significantly increase when DNA damage repair is inadequate. Most importantly, our research provides embryo models to study cell cycle regulation and DNA damage response under condition of different levels of oxidative stress

Concomitant Retrograde Coronary Venous Infusion of Basic Fibroblast Growth Factor Enhances Engraftment and Differentiation of Bone Marrow Mesenchymal Stem Cells for Cardiac Repair after Myocardial Infarction.

AIM: Basic fibroblast growth factor (bFGF) increases the migration and viability of bone marrow mesenchymal stem cells (MSCs) in vitro. Retrograde coronary venous infusion can provide both increased regional bFGF concentrations and homogeneous cell dissemination. We determined whether retrograde delivery of bFGF enhances the potency of transplanted MSCs for cardiac repair in a canine infarct model. METHODS AND RESULTS: Under hypoxic conditions, cellular migration was significantly increased in MSCs co-cultured with bFGF compared to vascular endothelial growth factor or insulin-like growth factor, and bFGF promoted MSCs differentiation into a cardiomyocyte phenotype. A canine infarct model was employed by coronary ligation. One week later, animals were subjected to retrograde infusion of combination bFGF (200ng/mL) and MSCs (1×10(8) cells) (n=5), MSCs (1×10(8) cells, n=5), bFGF (200ng/mL, n=5), or placebo (phosphate-buffered saline, n=3). Four weeks after infusion, only the bFGF+MSCs therapy exhibited significantly increased left ventricular ejection fraction (LVEF) by echocardiography (p CONCLUSIONS: Retrograde coronary venous bFGF infusion augments engraftment and differentiation capacity of transplanted MSCs, recovering cardiac function and preventing adverse remodeling. This novel combined treatment and delivery method is a promising strategy for cardiac repair after ischemic injury

Early ACEI/ARB use and in-hospital outcomes of acute myocardial infarction patients with systolic blood pressure <100 mmHg and undergoing percutaneous coronary intervention: Findings from the CCC-ACS project

BackgroundFew studies have evaluated whether acute myocardial infarction (AMI) patients with relatively low blood pressure benefit from early ACEI/ARB use in the era of percutaneous coronary intervention (PCI).ObjectivesThis study evaluated the associations of ACEI/ARB use within 24 h of admission with in-hospital outcomes among AMI patients with SBP < 100 mmHg and undergoing PCI.MethodsThis study was based on the Improving Care for Cardiovascular Disease in China-ACS project, a collaborative registry and quality improvement project of the American Heart Association and the Chinese Society of Cardiology. Between November 2014 and December 2019, a total of 94,623 patients with AMI were enrolled. Of them, 4,478 AMI patients with SBP < 100 mmHg and undergoing PCI but without clinically diagnosed cardiogenic shock at admission were included. Multivariable logistic regression and propensity score-matching analysis were used to evaluate the association between early ACEI/ARB use and in-hospital major adverse cardiac events (MACEs), a combination of all-cause death, cardiogenic shock, and cardiac arrest.ResultsOf AMI patients, 24.41% (n = 1,093) were prescribed ACEIs/ARBs within 24 h of admission. Patients with early ACEI/ARB use had a significantly lower rate of MACEs than those without ACEI/ARB use (1.67% vs. 3.66%, p = 0.001). In the logistic regression analysis, early ACEI/ARB use was associated with a 45% lower risk of MACEs (odds ratio: 0.55, 95% CI: 0.33–0.93; p = 0.027). Further propensity score-matching analysis still showed that patients with early ACEI/ARB use had a lower rate of MACEs (1.96% vs. 3.93%, p = 0.009).ConclusionThis study found that among AMI patients with an admission SBP < 100 mmHg undergoing PCI, early ACEI/ARB use was associated with better in-hospital outcomes. Additional studies of the early use of ACEIs/ARBs in AMI patients with relatively low blood pressure are warranted

Rationale and Design of the RESTORE Trial: A Multicenter, Randomized, Double-Blinded, Parallel-Group, Placebo-Controlled Trial to Evaluate the Effect of Shenfu Injection on Myocardial Injury in STEMI Patients After Primary PCI

BACKGROUND: The mortality following ST-segment elevation myocardial infarction (STEMI) remains substantial in the reperfusion era. Shenfu injection, as a traditional Chinese herbal formula, can alleviate ischemia-reperfusion injury through multiple pharmacologic effects. However, no robust data are available regarding the role of Shenfu injection in reducing infarct size for patients with STEMI undergoing primary percutaneous coronary intervention (PPCI). METHODS/DESIGN: This RESTORE trial is a multicenter, randomized, double-blind, parallel-group, placebo-controlled trial (NCT04493840). A total of 326 eligible patients with first-time anterior STEMI undergoing PPCI within 12 h of symptom onset will be enrolled from 10 centers in mainland China. Patients are randomized in a 1:1 fashion to receive either intravenous Shenfu injection (80mL Shenfu injection + 70mL 5% glucose injection) or placebo group (150mL 5% glucose injection) before reperfusion and followed by once a day until 5 days after PPCI. The primary end point is infarct size assessed by cardiac magnetic resonance (CMR) imaging 5±2 days after PPCI. The major secondary end points include enzymatic infarct size, microvascular obstruction, intramyocardial hemorrhage, left ventricular volume and ejection fraction assessed by CMR, as well as cardiovascular events at 30 days. CONCLUSIONS: The RESTORE trial is sufficiently powered to demonstrate the clinical effects of Shenfu injection on myocardial injury in STEMI patients undergoing PPCI in the contemporary era

Myo-inositol supported heterometallic Dy24M2 (M = Ni, Mn) cages

973 project from the Ministry of Science and Technology of China [2012CB821704]; National Natural Science Foundation of China [21371144, 21390390, 90922031]; Foundation for the Author of National Excellent Doctoral Dissertation of PR China [201219]Two heterometallic cage-like Dy24M2 (M = Ni, Mn) cluster compounds have been synthesized through self-assembly of the metal ions and myo-inositol ligand templated by three ClO4- anions

一. 新潁鹼金屬鉬酸銻之合成輿晶體結構研究 二. 鈣釩磷酸鹽之合成輿晶體結構研究

在兩年的研究中，以化合物之系列與不同的合成方法，將論文分為兩大部份：第一部 份為高溫固態反應法合成出鉀的鉬酸銻化合物-KSbMo O及鋰的鉬酸銻化合物-LiSbMo O . 第二部份的以高壓水熱法(hydrothermal)合成出鈣釩磷酸鹽化合物-Ca VO(PO ) 以及含有一個結晶水的鈣釩磷酸鹽化合物-Ca V(PO ) (HPO ) H O‧ 含有Sb 的鉬酸鹽相當罕見，在研究A-Sb -Mo -O (A = 鹼金屬) 過程中，我們合 成了KSbMo O 與LiSbMo O . 儘管兩者的化學式類似，但它們的結構卻是大大不同。 其中KSbMo O 為三斜晶系(Triclinic) ，空間群為P 1.晶格常數分別為a = 5.015(2) , b = 7.4216(6) , c = 10.304(1) , α= 90.45(1)°, β= 100.29(2)°, r = 10 7.79(1)°, V = 358. , Z = 2. R = 0.028, Rw = 0.034.而LiSbMo O 晶體為單斜 晶系(Monoclinic)，空間群為C2/c, a = 21.640(6) , b = 4.9305(7) , c = 5.5448 (6) , β= 100.35°, V = 582.0(2) , Z = 4. R = 0.026, Rw = 0.034. 前者具新 穎結構，後者卻與α- Sb O , NbSbO 等結構相關。論文中將詳細探討它們的合成與 晶體結構。 在利用高壓水熱法研究Ca-V-P-O系統中，發現了兩個新的化合物，儘管兩者之反應起 始物極其類似，但在反應條件差異的情況下，一個為溫度450° ，壓力為1 kbar；另 一僅在溫度230° 下反應，所產生出的產物結構卻完全不同。得到Ca (VO) (PO ) 的晶體為正交晶系(Orthorhombic)，空間群為Fdd2. 晶格常數a = 11.783(2) , b = 15.775(3) , c = 7.168(1) , V = 1329.60(2) , Z = 4. 至於Ca V(PO ) (HPO ) H O 晶體為單斜晶系(Monoclinic)，空間群則為C2/C，而晶格常數分別為a = 7.531( 2) , b= 15.522(4) , c = 9.149(2) , β= 113.52(2) , V = 980.7(5), Z = 4.論 文中亦將討論這兩者的合成與晶體結構。 #50007991 #5000799